Rocket Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), an investigational gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I). The FDA has set a Prescription Drug User Fee Act (PDUFA) date of March 28, 2026, for its decision. This BLA resubmission is supported by positive clinical data showing 100% overall survival at 12 months post-infusion among treated patients. If approved, Rocket Pharmaceuticals may be eligible for a Rare Pediatric Disease Priority Review Voucher. No grant or funding announcement involving multiple organizations was disclosed.